The OncLive Myeloproliferative Neoplasms condition center is a comprehensive resource for clinical news and expert insights on myeloproliferative neoplasms, including myelofibrosis, polycythemia vera, and essential thrombocythemia. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in myeloproliferative neoplasms.
Prolonged Overall Survival Observed With Oral Decitabine/Cedazuridine in MDS and CMML
September 24th 2021Updated data from the phase 3 ASCERTAIN trial demonstrated that the oral, fixed-duration combination of decitabine and cedazuridine induced a median overall survival of 31.7 months in patients with intermediate- and high-risk myelodysplastic syndrome, including chronic myelomonocytic leukemia.
A Changing Tide for Patients With Myelofibrosis
September 14th 2021The hallmarks of myelofibrosis—including clonal myeloproliferation, bone marrow fibrosis, anemia, splenomegaly, and constitutional symptoms—are associated with risk of morbidity and mortality; however, the recent advent of novel combinations and sequencing strategies have built on the foundation of care established with JAK2 inhibitors.
Transfusion Independence With Momelotinib Could Inform Treatment Decisions in Myelofibrosis
September 14th 2021The investigational JAK inhibitor momelotinib is effective at treating anemia in patients with myelofibrosis, resulting in improved rates of transfusion independence compared with ruxolitinib.
Palbociclib/Ruxolitinib Combo Shows Preclinical Promise in Myelofibrosis
August 19th 2021Palbociclib plus ruxolitinib led to normalized blood leukocyte counts, reduced splenomegaly, and significantly improved bone marrow fibrosis in JAK2 V617F and MPLW515L mouse models of myelofibrosis, suggesting that the combination could provide therapeutic benefit to patients with the malignancy.
Rusfertide Could Represent New Therapeutic Option in Polycythemia Vera
Marina Kremyanskaya, MD, PhD, discussed the results of the phase 2 PTG-300-04 trial, which were presented at the European Hematology Association 2021 Virtual Congress, and the potential for rusfertide as a treatment option for patients with polycythemia vera.